Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of Kitov Pharma (NASDAQ: KTOV) have fallen on Friday despite the company announcing that it has received notification from the Chinese patent office to grant two separate patents…
The patents (CM24 and NT219) are for Kitov’s leading oncology products for cancer patients. The CM24 patent was previously granted in the US, EU and multiple other countries.
“China represents a key target market for Kitov and an opportunity for potential collaboration partners. We believe that our growing intellectual property portfolio in China is critical in supporting our goal of establishing a potential market for CM24 and NT219, if approved, in this large territory,” said Isaac Israel, Kitov’s Chief Executive Officer.
KTOV stock price…
Kitov’s share price has failed to provide a positive reaction to the news and, after initially climbing over 1% higher, it is now trading down 1.53% at $3.87 per share.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .